SION Form 4: Cloonan executes 10b5-1 plan, exercises options and sells shares
Rhea-AI Filing Summary
Sionna Therapeutics director and CEO Michael Cloonan reported option exercises and sales executed under a Rule 10b5-1 plan. On 08/26/2025 and 08/27/2025 he exercised options with a $6.11 exercise price covering 17,574 and 7,426 shares respectively. Those exercises increased exercisable option counts and were followed by sales of the same share amounts at weighted-average prices of $24.96 and $25.0086, reducing his direct holdings to 547,343 shares. The Form 4 notes the 10b5-1 plan was adopted May 21, 2025, and the underlying options vest monthly through March 1, 2032.
Positive
- Use of a documented Rule 10b5-1 trading plan (adopted May 21, 2025) provides procedural compliance and pre-clearance for sales
- Realized value from option exercises at a $6.11 strike while selling at ~ $25 per share
- Substantial retained ownership: reporting person still owns 547,343 shares after transactions
- Clear vesting schedule disclosed for options (monthly through March 1, 2032) aiding transparency
Negative
- Significant open-market sales (25,000 total shares sold across two days) reduced the reporting person's direct holdings
- Weighted-average sale prices disclosed only as ranges with commitment to provide per-trade details on request, limiting immediate granularity
Insights
TL;DR: Routine insider option exercises and plan-based sales; liquidity event but not a clear signal of material corporate change.
The filing documents option exercises at a $6.11 strike and contemporaneous open-market sales executed under a 10b5-1 plan at ~25.00 per share, crystallizing intrinsic value while retaining a large ownership stake (547,343 shares). This is a common executive liquidity action that increases realized compensation without indicating operational changes. No debt, revenue or guidance data are included to alter valuation models.
TL;DR: Transactions follow a pre-established 10b5-1 plan and include standard vesting disclosures; governance practices appear compliant.
The report explicitly states the 10b5-1 plan adoption date and provides weighted-average sale price ranges and vesting schedule for options vesting monthly through 2032. The inclusion of an attorney-in-fact signature and clear disclosure of direct ownership supports regulatory compliance and transparency for insiders' trading activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 7,426 | $0.00 | -- |
| Exercise | Common Stock | 7,426 | $6.11 | $45K |
| Sale | Common Stock | 7,426 | $25.0086 | $186K |
| Exercise | Non-Qualified Stock Option (right to buy) | 17,574 | $0.00 | -- |
| Exercise | Common Stock | 17,574 | $6.11 | $107K |
| Sale | Common Stock | 17,574 | $24.96 | $439K |
Footnotes (1)
- This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.75 to $25.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.80 to $25.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date.
